search
Back to results

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Placebo
ISIS 757456
Sponsored by
Ionis Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Hypertensive, AGT, Angiotensinogen, Blood Pressure

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Males or females aged 18-75 inclusive and weighing ≥ 50 kilograms (kg) at the time of informed consent
  • Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal
  • Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential (WOCBP), the participant or participant's non-pregnant female partner must be using a highly effective contraceptive method
  • Body mass index (BMI) ≤ 35.0 kg/square meter (m^2)
  • Participant must have been diagnosed with essential hypertension for a minimum of 3 months prior to screening
  • At screening, the participant must have been on a stable regimen of 2 to 3 antihypertensive medications for at least 1 month prior to screening and will be required to maintain this regimen throughout the study, using either an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB), as well as 1 or 2 additional antihypertensive medications in the following categories: beta blocker, acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, nadolol, nebivolol, propranolol, pindolol, calcium channel blocker or, non-potassium sparing diuretic

Exclusion Criteria:

  • Clinically significant abnormalities in medical history, screening laboratory results, or physical examination that would render the participant unsuitable for inclusion
  • History of secondary HTN
  • The use of the following at time of screening and during the course of the study:

    • Other medications for the treatment of HTN (e.g., clonidine, guanfacine, guanabenz, alpha-methyldopa, hydralazine, minoxidil, diazoxide, renin inhibitors)
    • Medications that may cause hyperkalemia (e.g., cyclosporine or tacrolimus, pentamidine, trimethoprim-sulfamethoxazole, all heparins)
    • Oral or SC anticoagulants (e.g., warfarin, rivaroxaban, apixaban, heparin, lovenox)
    • Organic nitrate preparations (e.g., nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, or pentaerythritol)
    • Phosphodiesterase 5 inhibitors (e.g., sildenafil, tadalafil, vardenafil, avanafil)
    • Potassium-sparing diuretics (e.g., eplerenone, spironolactone, amiloride, triamterene)
  • Unstable/underlying cardiovascular disease defined as:

    • Any history of congestive heart failure (New York Heart Association [NYHA] class II-IV)
    • Any history of previous stroke, transient ischemic attack, unstable or stable angina pectoris, or myocardial infarction prior to screening
    • 12-lead electrocardiogram (ECG) corrected using Fridericia's formula (QTcF) > 450 milliseconds (msec) in males and > 470 msec in females at screening, or a history or evidence of long QT syndrome
    • Any clinically significant active atrial or ventricular arrhythmias
    • Any history of coronary bypass or percutaneous coronary intervention

Sites / Locations

  • Central Alabama Research
  • National Research Institute - Wilshire
  • Orange County Research Center
  • Excel Medical Clinical Trials
  • Progressive Medical Research
  • Midwest Institute for Clinical Research
  • Ohio Clinical Research - Lyndhurst
  • Juno Research, LLC
  • York Clinical Research LLC

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

ISIS 757456

Arm Description

Participants received ISIS 757456-matching placebo, subcutaneous (SC) injection, once-weekly for 8 weeks and an additional loading dose on Day 3.

Participants received ISIS 757456 80 mg, SC injection, once-weekly for 8 weeks and an additional loading dose on Day 3.

Outcomes

Primary Outcome Measures

Percent Change From Baseline in Plasma Angiotensinogen (AGT) at Day 57 Compared to Placebo
The baseline for plasma AGT was defined as the average of all values prior to the first dose of study drug.

Secondary Outcome Measures

Change From Baseline in Systolic Blood Pressure (SBP) at Each Scheduled, Post-Baseline Visit
Absolute Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit
The baseline for plasma AGT was defined as the average of all values prior to the first dose of study drug
Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit
The baseline for plasma AGT was defined as the average of all values prior to the first dose of study drug.

Full Information

First Posted
September 6, 2019
Last Updated
December 21, 2022
Sponsor
Ionis Pharmaceuticals, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04083222
Brief Title
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx
Official Title
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously for 8 Weeks to Hypertensive Subjects With Uncontrolled Blood Pressure
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
November 13, 2019 (Actual)
Primary Completion Date
July 20, 2020 (Actual)
Study Completion Date
July 20, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ionis Pharmaceuticals, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluated the effect of ISIS 757456 (IONIS-AGT-LRx) on plasma angiotensinogen (AGT) and systolic blood pressure (SBP) in uncontrolled hypertensive participants who were on two to three antihypertensive medications.
Detailed Description
This study was a Phase 2, double-blind, randomized, placebo-controlled study in 26 participants. Participants were randomized in a 2:1 ratio and received a once-weekly subcutaneous (SC) treatment with either IONIS-AGT-LRx or placebo, with an additional loading dose administered on Study Day 3. The treatment lasted for 8 weeks and the post-treatment period lasted for 13 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Hypertensive, AGT, Angiotensinogen, Blood Pressure

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants received ISIS 757456-matching placebo, subcutaneous (SC) injection, once-weekly for 8 weeks and an additional loading dose on Day 3.
Arm Title
ISIS 757456
Arm Type
Experimental
Arm Description
Participants received ISIS 757456 80 mg, SC injection, once-weekly for 8 weeks and an additional loading dose on Day 3.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
ISIS 757456-matching placebo solution administered as SC injection.
Intervention Type
Drug
Intervention Name(s)
ISIS 757456
Intervention Description
ISIS 757456 administered as SC injection.
Primary Outcome Measure Information:
Title
Percent Change From Baseline in Plasma Angiotensinogen (AGT) at Day 57 Compared to Placebo
Description
The baseline for plasma AGT was defined as the average of all values prior to the first dose of study drug.
Time Frame
Baseline up to Day 57 (start of Week 9)
Secondary Outcome Measure Information:
Title
Change From Baseline in Systolic Blood Pressure (SBP) at Each Scheduled, Post-Baseline Visit
Time Frame
Baseline, Days 3, 8, 15, 22, 29, 36, 43, 50, 57, 64, 78, 92, 120, and 141
Title
Absolute Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit
Description
The baseline for plasma AGT was defined as the average of all values prior to the first dose of study drug
Time Frame
Baseline, Days 3, 8, 15, 22, 29, 36, 43, 50, 57, 64, 78, 92, 120, and 141
Title
Percent Change From Baseline in Plasma AGT at Each Scheduled, Post-Baseline Visit
Description
The baseline for plasma AGT was defined as the average of all values prior to the first dose of study drug.
Time Frame
Baseline, Days 3, 8, 15, 22, 29, 36, 43, 50, 64, 78, 92, 120, and 141

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Males or females aged 18-75 inclusive and weighing ≥ 50 kilograms (kg) at the time of informed consent Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential (WOCBP), the participant or participant's non-pregnant female partner must be using a highly effective contraceptive method Body mass index (BMI) ≤ 35.0 kg/square meter (m^2) Participant must have been diagnosed with essential hypertension for a minimum of 3 months prior to screening At screening, the participant must have been on a stable regimen of 2 to 3 antihypertensive medications for at least 1 month prior to screening and will be required to maintain this regimen throughout the study, using either an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB), as well as 1 or 2 additional antihypertensive medications in the following categories: beta blocker, acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, nadolol, nebivolol, propranolol, pindolol, calcium channel blocker or, non-potassium sparing diuretic Exclusion Criteria: Clinically significant abnormalities in medical history, screening laboratory results, or physical examination that would render the participant unsuitable for inclusion History of secondary hypertension (HTN) The use of the following at time of screening and during the course of the study: Other medications for the treatment of HTN (e.g., clonidine, guanfacine, guanabenz, alpha-methyldopa, hydralazine, minoxidil, diazoxide, renin inhibitors) Medications that may cause hyperkalemia (e.g., cyclosporine or tacrolimus, pentamidine, trimethoprim-sulfamethoxazole, all heparins) Oral or SC anticoagulants (e.g., warfarin, rivaroxaban, apixaban, heparin, lovenox) Organic nitrate preparations (e.g., nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, or pentaerythritol) Phosphodiesterase 5 inhibitors (e.g., sildenafil, tadalafil, vardenafil, avanafil) Potassium-sparing diuretics (e.g., eplerenone, spironolactone, amiloride, triamterene) Unstable/underlying cardiovascular disease defined as: Any history of congestive heart failure (New York Heart Association [NYHA] class II-IV) Any history of previous stroke, transient ischemic attack, unstable or stable angina pectoris, or myocardial infarction prior to screening 12-lead electrocardiogram (ECG) corrected using Fridericia's formula (QTcF) > 450 milliseconds (msec) in males and > 470 msec in females at screening, or a history or evidence of long QT syndrome Any clinically significant active atrial or ventricular arrhythmias Any history of coronary bypass or percutaneous coronary intervention
Facility Information:
Facility Name
Central Alabama Research
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Facility Name
National Research Institute - Wilshire
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Orange County Research Center
City
Tustin
State/Province
California
ZIP/Postal Code
92780
Country
United States
Facility Name
Excel Medical Clinical Trials
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33434
Country
United States
Facility Name
Progressive Medical Research
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32127
Country
United States
Facility Name
Midwest Institute for Clinical Research
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46260
Country
United States
Facility Name
Ohio Clinical Research - Lyndhurst
City
Lyndhurst
State/Province
Ohio
ZIP/Postal Code
44124
Country
United States
Facility Name
Juno Research, LLC
City
Houston
State/Province
Texas
ZIP/Postal Code
77040
Country
United States
Facility Name
York Clinical Research LLC
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23510
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx

We'll reach out to this number within 24 hrs